CN104080472A - 用于在抑制或预防肿瘤生长中使用的骨桥蛋白变体和包含这类骨桥蛋白变体的组合物 - Google Patents

用于在抑制或预防肿瘤生长中使用的骨桥蛋白变体和包含这类骨桥蛋白变体的组合物 Download PDF

Info

Publication number
CN104080472A
CN104080472A CN201280068303.6A CN201280068303A CN104080472A CN 104080472 A CN104080472 A CN 104080472A CN 201280068303 A CN201280068303 A CN 201280068303A CN 104080472 A CN104080472 A CN 104080472A
Authority
CN
China
Prior art keywords
opn
seq
variant
active
molecule
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201280068303.6A
Other languages
English (en)
Chinese (zh)
Inventor
苏珊·R·里特林
彼得·朗堡·魏谢
安雅·塞丽娜
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Forsyth Children's Stomatological Hospital (under Name Of Forsyth Institute)
Arla Foods AMBA
Original Assignee
Forsyth Children's Stomatological Hospital (under Name Of Forsyth Institute)
Arla Foods AMBA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Forsyth Children's Stomatological Hospital (under Name Of Forsyth Institute), Arla Foods AMBA filed Critical Forsyth Children's Stomatological Hospital (under Name Of Forsyth Institute)
Publication of CN104080472A publication Critical patent/CN104080472A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/17—Amino acids, peptides or proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Veterinary Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Mycology (AREA)
  • Polymers & Plastics (AREA)
  • Food Science & Technology (AREA)
  • Nutrition Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Oncology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
CN201280068303.6A 2011-12-07 2012-12-07 用于在抑制或预防肿瘤生长中使用的骨桥蛋白变体和包含这类骨桥蛋白变体的组合物 Pending CN104080472A (zh)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201161567899P 2011-12-07 2011-12-07
US61/567,899 2011-12-07
US201261673912P 2012-07-20 2012-07-20
EP12177329.5 2012-07-20
EP12177329 2012-07-20
US61/673,912 2012-07-20
PCT/US2012/068628 WO2013086459A1 (en) 2011-12-07 2012-12-07 Osteopontin variants for use in suppression or prevention of tumor growth and compositions containing such osteopontin variants

Publications (1)

Publication Number Publication Date
CN104080472A true CN104080472A (zh) 2014-10-01

Family

ID=48574961

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201280068303.6A Pending CN104080472A (zh) 2011-12-07 2012-12-07 用于在抑制或预防肿瘤生长中使用的骨桥蛋白变体和包含这类骨桥蛋白变体的组合物

Country Status (12)

Country Link
US (1) US20150344534A1 (https=)
EP (1) EP2788015A1 (https=)
JP (1) JP2015500836A (https=)
KR (1) KR20140104474A (https=)
CN (1) CN104080472A (https=)
AR (1) AR089136A1 (https=)
AU (1) AU2012347468A1 (https=)
BR (1) BR112014013565A2 (https=)
CA (1) CA2858379A1 (https=)
EA (1) EA201491010A1 (https=)
WO (1) WO2013086459A1 (https=)
ZA (1) ZA201404920B (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2656474T3 (es) 2013-07-05 2018-02-27 Arla Foods Amba Osteopontina láctea de origen mamífero para potenciar la capacidad de respuesta inmune
EP4326758A4 (en) * 2021-04-20 2025-03-19 University of Cincinnati A vaccine adjuvant for infectious diseases

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000063241A2 (en) * 1999-04-15 2000-10-26 Children's Medical Center Corporation Methods and compositions for modulating an immune response

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5888552A (en) * 1988-04-29 1999-03-30 Immunotec Research Corporation Ltd. Anti-cancer therapeutic compositions containing whey protein concentrate
IL106576A (en) * 1992-08-13 2000-08-13 Immunotec Res Corp Ltd Anti-cancer therapeutic compositions for prophylaxis or for treatment of cancer
US7259243B2 (en) * 2000-01-07 2007-08-21 Arla Foods Amba Process for isolation of osteopontin from milk
NZ507335A (en) * 2000-10-05 2004-10-29 New Zealand Dairy Board Bone health compositions derived from milk comprising an acidic protein fraction but that does not contain CGMP
JP4509114B2 (ja) * 2003-09-18 2010-07-21 アルラ・フーズ・エイ・エム・ビィ・エイ 幼児用調製乳
SM200600031B (it) * 2006-10-06 2009-05-11 Gianluca Mech Integratore alimentare con attivatore proteico
ES2538362T3 (es) * 2007-10-16 2015-06-19 Ventana Medical Systems, Inc. Clasificación, estadificación y pronóstico del cáncer mediante el uso de osteopontina-C

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000063241A2 (en) * 1999-04-15 2000-10-26 Children's Medical Center Corporation Methods and compositions for modulating an immune response

Also Published As

Publication number Publication date
EA201491010A1 (ru) 2015-01-30
AR089136A1 (es) 2014-07-30
EP2788015A1 (en) 2014-10-15
WO2013086459A1 (en) 2013-06-13
KR20140104474A (ko) 2014-08-28
AU2012347468A1 (en) 2014-06-26
BR112014013565A2 (pt) 2019-09-24
ZA201404920B (en) 2015-12-23
US20150344534A1 (en) 2015-12-03
CA2858379A1 (en) 2013-06-13
JP2015500836A (ja) 2015-01-08

Similar Documents

Publication Publication Date Title
EP2421562B1 (en) Treatment of ovarian cancer using an anticancer agent conjugated to an angiopep-2 analog
US20200339642A1 (en) Glycoproteins having lipid mobilizing properties and therapeutic uses thereof
EP2061510B1 (en) Treatment and/or prevention of barrett's esophagus using anti-ephb4 antibody-containing compositions
JP6831135B2 (ja) 転移性卵巣癌、子宮内膜癌もしくは乳癌の予防または治療用組成物
JP2020524141A (ja) がんを処置するための方法および組成物
RU2389507C2 (ru) Лечение рака
US7871765B2 (en) Composition having antitumor effect
CN104080472A (zh) 用于在抑制或预防肿瘤生长中使用的骨桥蛋白变体和包含这类骨桥蛋白变体的组合物
CN104640989A (zh) 用于抑制或防止肿瘤生长的骨桥蛋白肽片段
CN118973599A (zh) 具有抗炎和抗纤维化活性的肽及其用途
KR101629560B1 (ko) 부작용이 억제된 암치료용 약학 조성물
US20230414712A1 (en) Pharmaceutical composition for preventing or treating cancer comprising recombinant stabilized galectin 9 protein
JP2023537338A (ja) がんのための併用療法
TW202128212A (zh) 一種具緩解抗癌藥物抗藥性及增加抗癌藥物敏感性之醫藥組合物及其用途
ES2747836T3 (es) Métodos y productos para prevenir y/o tratar el cáncer metastásico
EP3824901B1 (en) Pharmaceutical composition and use for applying ganoderma microsporum immunomodulatory protein and keyhole limpet hemocyanin in carcinoma treatment
EP4005583A1 (en) Cp2c-targeting peptide-based anticancer agent
US20220273755A1 (en) Pharmaceutical composition, use and method for applying ganoderma microsporum immunomodulatory protein and keyhole limpet hemocyanin in carcinoma treatment
US20240417812A1 (en) Methods for treating solid cancer patients with clonal hematopoiesis of indeterminate potential
US20250049902A1 (en) Method of Developing a Peptide-Based Vaccine Conjugated with 1V209
WO2023072968A1 (en) Compositions comprising bacterial strains
WO2024188333A1 (zh) 瑞帕利辛单药或联合抗pd-1抗体用于治疗疾病的方法
KR20260037499A (ko) 루핀 알칼로이드계 화합물을 포함하는 미세먼지 유발 호흡기 질환의 예방 또는 치료용 조성물
KR101608141B1 (ko) 클라스린 발현 저해 물질을 유효 성분으로 포함하는 파브리 질환의 예방 또는 치료용 조성물
KR20210111043A (ko) HopQ를 포함하는 암전이 억제용 조성물

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20141001